Tretinoin

Timber Pharmaceuticals, Inc., a LEO Pharma Company, Presents Late-Breaking Preliminary Results of TMB-001 in Moderate-to-Severe Congenital Ichthyosis (CI) at the 2024 AAD Annual Meeting

Retrieved on: 
Sunday, March 10, 2024
Biotechnology, Pharmaceutical, Health, Clinical Trials, LEO, Leo Pharma, Disease, Associate, Patient, Ageing, PKS, Knowledge, Research, American Academy, Acquisition, Tretinoin, Adolescence, Abstract, Yale School of Medicine, Clinical trial, Safety, AAD, Isotretinoin, ISO, FDA, Fissure, ASCEND, IGA, Food, Pharmaceutical industry

“With no specific treatment currently available, CI patients are currently having to deal with their condition with minimal support.

Key Points: 
  • “With no specific treatment currently available, CI patients are currently having to deal with their condition with minimal support.
  • I hope that the data and insights presented today can help provide new knowledge and support for this patient community.”
    In January 2024, LEO Pharma finalized the acquisition of Timber Pharmaceuticals, a clinical-stage biopharmaceutical company focused on the development and commercialization of treatments for rare and orphan dermatologic diseases.
  • Upon completion, the Timber Pharmaceuticals lead investigational product candidate, TMB-001, was added to LEO Pharma’s pipeline.
  • TMB-001 is under investigation and has not been evaluated by any health authority.

Notable Labs Announces JCO Precision Oncology Publication Demonstrating PPMP Potential to Identify Novel Drug Combinations in JMML

Retrieved on: 
Thursday, November 9, 2023
EHA, CD38, Associate, UCSF Benioff Children's Hospital, European Hematology Association, Juvenile myelomonocytic leukemia, Transplant, Disease, Database, UCSF, Patient, ASCO, Hematopoietic stem cell transplantation, APL, AZA, Blood, Cytarabine, FLA, Cancer, Tretinoin, Acute promyelocytic leukemia, Trial of the century, Malignancy, Society, Physician, Cell, Bone marrow, Drug combination, Pharmaceutical industry, JMML

FOSTER CITY, Calif., Nov. 09, 2023 (GLOBE NEWSWIRE) -- Notable Labs, Inc. (“Notable”) (Nasdaq: NTBL), a clinical stage therapeutic platform company developing predictive precision medicines for cancer patients, today announced the publication of data from an ex vivo study demonstrating the potential for its Predictive Precision Medicine Platform (PPMP) to identify more effective pre-hematopoietic stem cell transplantation (pre-HSCT) regimens for the treatment of juvenile myelomonocytic leukemia (JMML) in the November 9th Issue of the American Society of Clinical Oncology (ASCO) Journal JCO Precision Oncology. Part of this data was recently presented at the European Hematology Association (EHA) Hybrid Congress held in Frankfurt, Germany on June 8 – 15, 2023. Details of that presentation can be found on the Company’s website at https://notablelabs.com/.

Key Points: 
  • JMML is a rare, aggressive pediatric malignancy for which curative treatment is restricted to hematopoietic stem cell transplantation.
  • Pre-HSCT therapies, i.e., therapies prior to transplantation, include moderately intensive chemotherapy (particularly fludarabine and cytarabine in combination (FLA)) and azacytidine (AZA) monotherapy.
  • Applying its proprietary PPMP technology to blood or bone marrow samples from JMML patients, Notable screened 130 drug combinations and discovered that 27 of these combinations (26 dual-, 1 triple-combination) were more effective ex vivo than the components of these combinations tested individually.
  • “This publication marks the culmination of a multi-year collaboration between UCSF and Notable Labs,” remarked Dr. Stieglitz.

Dr. Rod J. Rohrich Selected by Newsweek as the Best Facelift Surgeon in the United States

Retrieved on: 
Tuesday, August 29, 2023
Anatomy, Science, Skin care, Surgeon, Physician, Smoking cessation, Tretinoin, Breast augmentation, Rhinoplasty, Patient, Face, Dentistry, Veterinary medicine, Creative industries, DALLAS, Newsweek

DALLAS, Aug. 29, 2023 /PRNewswire-PRWeb/ -- Dallas plastic surgeon, Dr. Rod J. Rohrich, has been selected as the top facelift surgeon in the United States for 2023 in Newsweek's newly published, peer reviewed list of top performing plastic surgeons, topping the list at number 1 for the third consecutive year.

Key Points: 
  • Renowned plastic surgeon, Dr. Rod J. Rohrich, has recently been selected by Newsweek as the best facelift surgeon in the United States for the third consecutive year in the magazine's ranked list of best plastic surgeons.
  • DALLAS, Aug. 29, 2023 /PRNewswire-PRWeb/ -- Dallas plastic surgeon, Dr. Rod J. Rohrich, has been selected as the top facelift surgeon in the United States for 2023 in Newsweek's newly published, peer reviewed list of top performing plastic surgeons, topping the list at number 1 for the third consecutive year.
  • In the resulting list, Dr. Rohrich was ranked at number 1 for the best facelift surgeon in the United States , with the top performing score based on the unique methodology used by Newsweek and Statista.
  • "I'm extremely honored to have my work in facelift surgery recognized by Newsweek in this extensive peer reviewed process," says Dr. Rohrich.

Retinol: what is it and why is it considered a modern anti-ageing skincare essential?

Retrieved on: 
Friday, August 4, 2023
Tretinoin, Retinoid, All-trans-retinyl ester 13-cis isomerohydrolase, Skin, US Foods, Instability, Oxygen, Elastin, Light, Acne, Vitamin A, Cosmetics, Research, Vegetable, Sale, Psoriasis, Sunlight, Retinal, Immune system, Growth, Collagen, ECM, Bacteria, Hand, Environment, Nanotechnology, Food, Scleroderma, Wound healing, Dietary supplement, Sulfur, EU, Atlantic Ocean

Of all the wonder ingredients promoted by skincare enthusiasts and manufacturers, retinol is among the most popular. It’s a potent ingredient that can help with a wide variety of complaints, from wrinkles to acne. But how does it work and should you just go out and buy the first retinol product you see?What is retinol?Vitamin A is an essential micronutrient that plays a vital role in supporting various physiological functions in most mammal species.

Key Points: 


Of all the wonder ingredients promoted by skincare enthusiasts and manufacturers, retinol is among the most popular. It’s a potent ingredient that can help with a wide variety of complaints, from wrinkles to acne. But how does it work and should you just go out and buy the first retinol product you see?

What is retinol?

    • Vitamin A is an essential micronutrient that plays a vital role in supporting various physiological functions in most mammal species.
    • It promotes normal vision, bolsters the immune system, facilitates reproduction and fosters optimal growth and development.
    • It can help maintain skin health and, because it stimulates collagen and elastin biosynthesis, it can enhance the skin’s regenerative mechanisms.

Retinol

    • When retinol is applied topically, it is converted into retinoic acid by the skin, the biologically active form of vitamin A.
    • This is why you often see retinol skincare products packaged in opaque bottles, which protect them from the sunlight.
    • Some manufacturers recommend keeping retinol products in the fridge, and most skincare retinol products have a limited shelf-life.

Retinyl

    • The most common forms are retinyl acetate and retinyl palmitate.
    • Retinyl needs to be converted into retinol and then into retinoic acid by the skin in order to be functional.

Retinaldehyde

    • Retinaldehyde, also known as retinal, is more potent than retinol but less potent than retinoic acid.
    • Due to its proximity to retinoic acid, retinaldehyde is considered more efficient in producing skin benefits compared with retinol.

Which to choose

    • Generally, over-the-counter cosmetic products may contain retinol concentrations ranging from 0.1% to 1%.
    • These concentrations are lower than prescription-strength retinoids, which can contain higher amounts of retinol or more potent derivatives such as tretinoin.
    • This is why you might see stronger retinol products on sale in markets such as the US, compared with Europe or countries that trade heavily with Europe.
    • The retinyl esters are the most stable but have not shown significant differences when used on the skin, compared with a placebo.

Timber Pharmaceuticals to Present Interim Analyses From Phase 3 ASCEND Study of TMB-001 in Congenital Ichthyosis

Retrieved on: 
Tuesday, June 20, 2023
Tretinoin, PK, Society, Dermis, Stanford University, Must, Food, CI, XLRI, Epidermis, Pediatric Dermatology, Dermatology, Toxicity, Absorption, Plasma, Ichthyosis, IGA, Professor, ASCEND, Patient, Collection, Lumber, Isotretinoin, Regulation of food and dietary supplements by the U.S. Food and Drug Administration, NYSE, Skin, Safety, ARCI, Body surface area, Pharmaceutical industry

WARREN, NJ, June 20, 2023 (GLOBE NEWSWIRE) -- via NewMediaWire – Timber Pharmaceuticals, Inc. ("Timber" or the “Company”) (NYSE American: TMBR), a clinical-stage biopharmaceutical company focused on the development and commercialization of treatments for rare and orphan dermatologic diseases, today announced that interim pharmacokinetic (PK) analyses from the Phase 3 ASCEND study indicate minimal systemic absorption of isotretinoin or its major metabolites in patients with moderate to severe forms of congenital ichthyosis (CI) who were treated with TMB-001 0.05% ointment. Full PK results will be presented during the Society for Pediatric Dermatology’s Annual Meeting to be held July 13-16, 2023, in Asheville, North Carolina.

Key Points: 
  • Full PK results will be presented during the Society for Pediatric Dermatology’s Annual Meeting to be held July 13-16, 2023, in Asheville, North Carolina.
  • The primary endpoint is the difference in proportions of treated patients with 2-point Investigator's Global Assessment (IGA) scaling/fissuring score improvement from baseline at 12 weeks.
  • The interim PK analyses include the first nine patients who completed 15 days of the MuST study.
  • The results indicate minimal absorption of isotretinoin when TMB-001 0.05% is applied to 75-90% of the body surface area.

Notable Labs Presents Data Demonstrating PPMP’s Potential to Identify Novel Drug Combinations in JMML at the 2023 EHA Hybrid Congress

Retrieved on: 
Friday, June 9, 2023
San Francisco, Tretinoin, University, European Hematology Association, CALC, University of California, San Francisco, Cancer, Juvenile myelomonocytic leukemia, Patient, Drug combination, Cytarabine, EHA, Calcitriol, Poster, Hospital, FLU, Pharmaceutical industry, JMML

FOSTER CITY, Calif., June 09, 2023 (GLOBE NEWSWIRE) -- Notable Labs, Inc. (“Notable”), a clinical stage therapeutic platform company developing predictive precision medicines for cancer patients, today presented data from an ex vivo study demonstrating the potential for its Predictive Precision Medicine Platform (PPMP) to identify more active investigational pre-hematopoietic stem cell therapy (pre-HCST) regimens for the treatment of juvenile myelomonocytic leukemia (JMML) at the European Hematology Association (EHA) Hybrid Congress being held in Frankfurt, Germany on June 8 – 15, 2023.

Key Points: 
  • Of 130 drug combinations, 27 were shown to be more active in killing leukemic cells ex vivo than compounds represented in these combinations on their own.
  • These results highlight PPMP as a potential tool for identifying superior drug combinations for patients with high medical needs, including with JMML.
  • Abstract title: Tretinoin and calcitriol enhance treatment regimens for juvenile myelomonocytic leukemia in ex vivo drug sensitivity assays.
  • Additional meeting information can be found on the 2023 EHA Congress website, https://ehaweb.org/congress/eha2023-hybrid-congress/eha2023/ .

Sol-Gel and Searchlight Pharma Announce Licensing Agreements to Commercialize TWYNEO® and EPSOLAY® in Canada

Retrieved on: 
Tuesday, June 6, 2023
Tretinoin, Rosacea, Partnership, Philosophy, Dermatology, Acquisition, Patient, Physician, NESS, OBI Pharma, Inc., Sol–gel process, Benzoyl peroxide, Health, Acne, Fine chemical, Pharmaceutical industry, Medical device

TWYNEO and EPSOLAY are two innovative, large-market, dermatology products that were developed by Sol-Gel.

Key Points: 
  • TWYNEO and EPSOLAY are two innovative, large-market, dermatology products that were developed by Sol-Gel.
  • Both products recently launched in the U.S., and Searchlight is to commercialize them in Canada over a fifteen-year term that is renewable for subsequent five-year periods.
  • In addition, Sol-Gel will be entitled to royalty percentages of all Canadian net sales ranging from low-double-digits to high teens.
  • We look forward to collaborating with Searchlight to maximize the presence of our two unique drugs, TWYNEO and EPSOLAY, in Canada, a leading commercial territory.”

Notable Labs to Present Predictive Precision Medicine Platform (PPMP) Data in Juvenile Myelomonocytic Leukemia (JMML) at European Hematology Association (EHA) Hybrid Congress June 8 – 15, 2023

Retrieved on: 
Wednesday, May 17, 2023
European Hematology Association, Tretinoin, Cancer, Patient, Drug combination, Cytarabine, EHA, Pharmaceutical industry, Medical imaging, JMML

FOSTER CITY, Calif., May 17, 2023 (GLOBE NEWSWIRE) -- Notable Labs, Inc. (“Notable”), a clinical stage therapeutic platform company developing predictive precision medicines for cancer patients, today announced an abstract has been accepted for poster presentation at the European Hematology Association (EHA) Hybrid Congress to be held in Frankfurt, Germany on June 8 – 15, 2023.

Key Points: 
  • FOSTER CITY, Calif., May 17, 2023 (GLOBE NEWSWIRE) -- Notable Labs, Inc. (“Notable”), a clinical stage therapeutic platform company developing predictive precision medicines for cancer patients, today announced an abstract has been accepted for poster presentation at the European Hematology Association (EHA) Hybrid Congress to be held in Frankfurt, Germany on June 8 – 15, 2023.
  • The abstract highlights results of a research study demonstrating the utility of Notable’s PPMP for identifying potentially more effective pre-hematopoietic stem cell therapy drug combinations, as compared to regimens currently used in JMML.
  • The study showed that the addition of tretinoin to fludarabine + cytarabine or to 5-azacitidine, or calcitriol to 5-azacitidine, to patients’ samples further reduced the ex vivo blast counts compared to treatment with only fludarabine + cytarabine, or 5-azacitidine, respectively.

Acne Drugs Market size to grow by USD 907.11 million from 2022 to 2027, Driven by the emergence of improved diagnostic modalities - Technavio

Retrieved on: 
Friday, April 14, 2023
Plasma protein binding, Dermatology, Infection, R, ARD, Geography, Cosmetics, Research, Tazarotene, Adapalene, Growth, Diagnosis, Gel, Skin, GSK plc, Neutrogena, Bayer, Emulsion, History, Mask, Swelling, Eastman Kodak Co. v. Image Technical Services, Inc., Diane, Sample, Viatris, Risk assessment, Woman, Acne, Inflammation, Physical examination, CAPEX, ROW, McKesson Corporation, Dry, Reckitt, Pharmaceutical industry, Sulfur, Fine chemical, Retail, Medical imaging, Veterinary medicine, Beauty salon, Tretinoin

The growth of the market will be driven by the emergence of improved diagnostic modalities, the launch of new acne drugs, and the increasing cases of acne.

Key Points: 
  • The growth of the market will be driven by the emergence of improved diagnostic modalities, the launch of new acne drugs, and the increasing cases of acne.
  • Acne drugs market Vendor Analysis:
    The global acne drugs market is highly fragmented and is expected to grow rapidly during the forecast period.
  • A major driver for the acne drugs market is the emergence of improved diagnostic modalities, and it is expected to have a positive impact on the market growth during the forecast period.
  • A major challenge hampering the growth of the acne drugs market is the presence of substitutes for acne drugs.

Curology Introduces Future-Proof Rx, a New Daily Preventative Aging Product That's Personalized for You

Retrieved on: 
Tuesday, April 4, 2023
Cream, Tretinoin, Elasticity, Nicotinamide, Nursing, Pharmacy, Ageing, Acne, Vitamin A, Inflammation, Tranexamic acid, Pigment, Target, Dermatology, Gold, Medical director, Patient, SAN, Hyperpigmentation, Skin, Cosmetics, Dietary supplement

SAN FRANCISCO, April 4, 2023 /PRNewswire/ -- Today, dermatologist-founded skincare company Curology is introducing its latest innovation - Future-ProofRx, a brand-new personalized prescription product that helps defend against and treat the earliest signs of aging while promoting glowing skin.

Key Points: 
  • As a result, the company developed a product called Future-ProofRx, designed to help prevent and address early signs of aging such as fine lines and dark spots.
  • "At Curology, we believe that all skin deserves expert care and our newest personalized prescription product, Future-ProofRx, expands our offering of personalized prescription skincare.
  • Existing patients should connect with their current Curology licensed dermatology provider to see if Future-ProofRx is right for them.
  • Future-ProofRx is the newest addition to Curology's lineup of personalized prescription skincare products, joining Curology's Custom FormulaRx for acne, which has been the company's core personalized prescription product since its launch in 2014.